Analysts tout market potential of Xenon's epilepsy drug on Phase III win [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
Analysts have touted the market potential of Xenon Pharmaceuticals' novel epilepsy drug, azetukalner, following a positive late-stage readout in patients with focal onset seizures (FOS). During the global, Phase III X-TOLE2 study (NCT05614063), both a high (25mg) and low (15mg) dose of azetukalner met the trial's primary endpoint, reducing the monthly frequency of FOS by 53.2% and 34.5% from baseline at week 12. This compares with a 10.4% reduction in FOS observed in patients given the placebo. According to William Blair analyst Miles Minter, results from the X-TOLE2 study “blow away” the company's expectations of =30% placebo-normalised improvement. Analysts at echoed this sentiment, noting that azetukalner's efficacy has "beaten already-high Street expectations". Other investors also seem optimistic about these results, as Xenon's stock value climbed 44% from $41.94 at market close on 6 March to $60.56 at opening on 9 March. Alongside clearing the efficacy bar set by invest
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.MarketBeat
- Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
XENE
Earnings
- 2/26/26 - Miss
XENE
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- XENE's page on the SEC website